Get the Latest Updates
with Juniper Biosciences

MSKCC announces FDA Breakthrough Therapy Designation for JBS-003 & Details Impact to Patients

FDA Reviewing Low-Dose Radiation To Treat HPV Throat Cancer With Fewer Side Effects

By Jim Stallard, Thursday, September 3, 2026

Juniper’s JBS-003 (F-MISO) Program Receives FDA Breakthrough Therapy Designation, Advancing a First-in-Class Hypoxia Tracer Enabling Radiation De-escalation in HPV-Positive Head and Neck Cancer

BEDMINSTER, N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) — Juniper Biosciences today announced that the U.S. Food and Drug...

Juniper Biosciences Appoints Renowned Radiopharmaceutical Expert Jason S. Lewis, Ph.D. as Chair of Newly Formed Scientific Advisory Board

Juniper Biosciences announced the launch of its Scientific Advisory Board and appointed Jason S. Lewis, Ph.D., as its inaugural Chair to help guide the development of its precision oncology pipeline.